儿童及青年癌症幸存者治疗后精子冷冻保存实践调查
该调查覆盖法国30个生育力保存中心及5个欧洲国家的9名生育专家,用8个临床病例和40个问题评估诊断年龄、治疗类型和精子参数对治疗后生育力保存提议概率的影响。结果显示,严重少弱畸精子症病例中100%专家提议冷冻保存,中度异常为77-88%,精子活力和活力受损为65-77%,精子参数正常时27-54%专家仍会提议;这些结果未因治疗类型或应答者因素而显著不同。结论认为治疗后精液分析可广泛提议给未受益于治疗前生育力保存的儿童癌症幸存者,持续中重度精子参数异常者可提议治疗后生育力保存,指南对统一实践和鼓励肿瘤科医生转诊很重要。
要点
- 严重少弱畸精子症病例中100%生育专家提议治疗后精子冷冻保存。
- 中度少弱畸精子症病例中77-88%专家提议,精子活力和活力受损病例中65-77%提议。
- 精子参数正常时27-54%专家仍提议治疗后精子冷冻保存。
核心结论
- 治疗后精液分析可广泛提议给未受益于治疗前生育力保存的儿童癌症幸存者。
- 持续中重度精子参数异常者可提议治疗后生育力保存。
- 指南对统一实践和鼓励肿瘤科医生转诊儿童癌症幸存者进行生育评估很重要。
研究设计与样本
- 调查法国全部30个生育力保存中心和5个欧洲国家的9名欧洲生育专家。
- 包含8个临床病例和40个问题,评估诊断年龄、治疗类型(烷化剂、睾丸切除术、睾丸放疗)和精子参数对治疗后生育力保存提议概率的影响。
- 收集应答医生的 demographic 特征。
主要发现
- 严重少弱畸精子症病例中100%生育专家提议治疗后精子冷冻保存。
- 中度少弱畸精子症病例中77-88%专家提议,精子活力和活力受损病例中65-77%提议。
- 精子参数正常时27-54%生育专家会提议治疗后精子冷冻保存。
- 这些结果未因接受的治疗类型或应答者相关因素而显著不同。
- 欧洲专家实践也受精子参数结果指导;44-67%专家表示在中重度精子参数异常病例中会提议精子冷冻保存。
关键数值与推荐
- 严重少弱畸精子症:100%专家提议治疗后精子冷冻保存。
- 中度少弱畸精子症:77-88%专家提议。
- 精子活力和活力受损:65-77%专家提议。
- 精子参数正常:27-54%专家提议。
- 中重度精子参数异常:44-67%欧洲专家表示会提议精子冷冻保存。
临床怎么用
- 治疗后精液分析可广泛提议给未受益于治疗前生育力保存的儿童癌症幸存者。
- 持续中重度精子参数异常者可提议治疗后生育力保存。
- 指南对统一实践和鼓励肿瘤科医生转诊儿童癌症幸存者进行生育评估很重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: What are current practices of post-treatment fertility preservation in male childhood cancer survivors (CCS) who have not benefitted from pre-therapeutic fertility preservation in France and other European countries? DESIGN: A survey was conducted of all fertility preservation centres in France (n = 30) and European fertility specialists (n = 9) in five European countries. Eight clinical cases and 40 questions were included to assess the effect of age at diagnosis, type of treatment (alkylating-agents, orchidectomy, testicular radiotherapy) and sperm parameters on the probability of a post-treatment fertility preservation proposal. Demographic characteristics of the responding practitioner were also collected. RESULTS: Post-treatment sperm cryopreservation was proposed by 100% of fertility specialists in cases of severe oligoasthenoteratozoospermia, 77-88% in cases of moderate oligoasthenoteratozoospermia and in 65-77% in cases of sperm motility and vitality impairment. In cases of normal sperm parameters, 27-54% of fertility specialists would propose post-treatment sperm cryopreservation. These results did not differ significantly according to the type of treatment received or to responder-related factors. Practices of European specialists were also guided by sperm parameter results; 44-67% of specialists responding that they would propose sperm cryopreservation in cases of moderate to severe sperm parameter alterations. CONCLUSION: Post-treatment semen analysis could be widely proposed to CCS who have not benefitted from pre-therapeutic fertility preservation. Post-treatment fertility preservation could be proposed in cases of persistent moderate to severe sperm parameter alterations. Guidelines would be important to homogenize practices and to encourage oncologists to refer CCS for fertility assessments.
引用
- Sarian G, Chalas C, Le Teuff G, et al. Post-treatment sperm cryopreservation practices in childhood and young adult cancer survivors. Reprod Biomed Online. 2023. PMID: 38113762. doi:10.1016/j.rbmo.2023.103573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。